Annual Accounts Payable
$55.52 M
-$42.58 M-43.40%
31 December 2023
Summary:
Alnylam Pharmaceuticals annual accounts payable is currently $55.52 million, with the most recent change of -$42.58 million (-43.40%) on 31 December 2023. During the last 3 years, it has risen by +$3.55 million (+6.84%). ALNY annual accounts payable is now -43.40% below its all-time high of $98.09 million, reached on 31 December 2022.ALNY Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Payable
$70.81 M
-$3.17 M-4.29%
30 September 2024
Summary:
Alnylam Pharmaceuticals quarterly accounts payable is currently $70.81 million, with the most recent change of -$3.17 million (-4.29%) on 30 September 2024. Over the past year, it has dropped by -$3.04 million (-4.11%). ALNY quarterly accounts payable is now -27.82% below its all-time high of $98.09 million, reached on 31 December 2022.ALNY Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ALNY Accounts Payable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -43.4% | -4.1% |
| 3 y3 years | +6.8% | +76.8% |
| 5 y5 years | -7.0% | +79.7% |
ALNY Accounts Payable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -43.4% | +6.8% | -27.8% | +76.8% |
| 5 y | 5 years | -43.4% | +11.3% | -27.8% | +171.0% |
| alltime | all time | -43.4% | +8137.2% | -27.8% | +7680.8% |
Alnylam Pharmaceuticals Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $70.81 M(-4.3%) |
| June 2024 | - | $73.98 M(-5.3%) |
| Mar 2024 | - | $78.15 M(+40.8%) |
| Dec 2023 | $55.52 M(-43.4%) | $55.52 M(-24.8%) |
| Sept 2023 | - | $73.84 M(+23.6%) |
| June 2023 | - | $59.75 M(-4.0%) |
| Mar 2023 | - | $62.24 M(-36.6%) |
| Dec 2022 | $98.09 M(+33.6%) | $98.09 M(+141.8%) |
| Sept 2022 | - | $40.57 M(-22.6%) |
| June 2022 | - | $52.42 M(-4.5%) |
| Mar 2022 | - | $54.92 M(-25.2%) |
| Dec 2021 | $73.43 M(+41.3%) | $73.43 M(+83.3%) |
| Sept 2021 | - | $40.05 M(-24.6%) |
| June 2021 | - | $53.08 M(+17.0%) |
| Mar 2021 | - | $45.38 M(-12.7%) |
| Dec 2020 | $51.97 M(+4.2%) | $51.97 M(+86.4%) |
| Sept 2020 | - | $27.87 M(+6.7%) |
| June 2020 | - | $26.13 M(-35.5%) |
| Mar 2020 | - | $40.48 M(-18.8%) |
| Dec 2019 | $49.88 M(-16.5%) | $49.88 M(+26.6%) |
| Sept 2019 | - | $39.39 M(-44.7%) |
| June 2019 | - | $71.22 M(+214.1%) |
| Mar 2019 | - | $22.67 M(-62.0%) |
| Dec 2018 | $59.71 M(+110.6%) | $59.71 M(+174.2%) |
| Sept 2018 | - | $21.77 M(+81.6%) |
| June 2018 | - | $11.99 M(-9.2%) |
| Mar 2018 | - | $13.21 M(-53.4%) |
| Dec 2017 | $28.36 M(-47.9%) | $28.36 M(+206.9%) |
| Sept 2017 | - | $9.24 M(-60.1%) |
| June 2017 | - | $23.17 M(-8.7%) |
| Mar 2017 | - | $25.37 M(-53.4%) |
| Dec 2016 | $54.47 M(+224.4%) | $54.47 M(+135.4%) |
| Sept 2016 | - | $23.14 M(+80.4%) |
| June 2016 | - | $12.82 M(-26.5%) |
| Mar 2016 | - | $17.44 M(+3.9%) |
| Dec 2015 | $16.79 M(+11.1%) | $16.79 M(+17.6%) |
| Sept 2015 | - | $14.27 M(-9.2%) |
| June 2015 | - | $15.71 M(+1.5%) |
| Mar 2015 | - | $15.49 M(+2.5%) |
| Dec 2014 | $15.11 M | $15.11 M(+190.5%) |
| Sept 2014 | - | $5.20 M(-15.7%) |
| June 2014 | - | $6.17 M(+22.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2014 | - | $5.04 M(-14.6%) |
| Dec 2013 | $5.90 M(+33.4%) | $5.90 M(+116.1%) |
| Sept 2013 | - | $2.73 M(-39.8%) |
| June 2013 | - | $4.53 M(+46.0%) |
| Mar 2013 | - | $3.10 M(-29.8%) |
| Dec 2012 | $4.42 M(-23.8%) | $4.42 M(-13.2%) |
| Sept 2012 | - | $5.09 M(-7.7%) |
| June 2012 | - | $5.52 M(+27.2%) |
| Mar 2012 | - | $4.34 M(-25.2%) |
| Dec 2011 | $5.80 M(-37.7%) | $5.80 M(+5.7%) |
| Sept 2011 | - | $5.49 M(-31.0%) |
| June 2011 | - | $7.95 M(+37.1%) |
| Mar 2011 | - | $5.80 M(-37.7%) |
| Dec 2010 | $9.31 M(-25.4%) | $9.31 M(+41.9%) |
| Sept 2010 | - | $6.56 M(-36.9%) |
| June 2010 | - | $10.40 M(+48.8%) |
| Mar 2010 | - | $6.99 M(-44.0%) |
| Dec 2009 | $12.49 M(+382.6%) | $12.49 M(+48.2%) |
| Sept 2009 | - | $8.43 M(+30.4%) |
| June 2009 | - | $6.46 M(-26.0%) |
| Mar 2009 | - | $8.73 M(+237.3%) |
| Dec 2008 | $2.59 M(-32.4%) | $2.59 M(-22.6%) |
| Sept 2008 | - | $3.34 M(-46.4%) |
| June 2008 | - | $6.24 M(-31.3%) |
| Mar 2008 | - | $9.08 M(+137.4%) |
| Dec 2007 | $3.83 M(-6.3%) | $3.83 M(-45.8%) |
| Sept 2007 | - | $7.06 M(+24.5%) |
| June 2007 | - | $5.67 M(+88.5%) |
| Mar 2007 | - | $3.01 M(-26.4%) |
| Dec 2006 | $4.08 M(+106.8%) | $4.08 M(+66.3%) |
| Sept 2006 | - | $2.46 M(-33.6%) |
| June 2006 | - | $3.70 M(-5.9%) |
| Mar 2006 | - | $3.93 M(+98.9%) |
| Dec 2005 | $1.98 M(+117.0%) | $1.98 M(-0.5%) |
| Sept 2005 | - | $1.99 M(+23.1%) |
| June 2005 | - | $1.61 M(-2.5%) |
| Mar 2005 | - | $1.65 M(+81.6%) |
| Dec 2004 | $910.00 K(-39.7%) | $910.00 K(-37.2%) |
| Sept 2004 | - | $1.45 M(-19.9%) |
| June 2004 | - | $1.81 M(-50.2%) |
| Mar 2004 | - | $3.64 M(+140.8%) |
| Dec 2003 | $1.51 M(+124.0%) | $1.51 M |
| Dec 2002 | $674.00 K | - |
FAQ
- What is Alnylam Pharmaceuticals annual accounts payable?
- What is the all time high annual accounts payable for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals annual accounts payable year-on-year change?
- What is Alnylam Pharmaceuticals quarterly accounts payable?
- What is the all time high quarterly accounts payable for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals quarterly accounts payable year-on-year change?
What is Alnylam Pharmaceuticals annual accounts payable?
The current annual accounts payable of ALNY is $55.52 M
What is the all time high annual accounts payable for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high annual accounts payable is $98.09 M
What is Alnylam Pharmaceuticals annual accounts payable year-on-year change?
Over the past year, ALNY annual accounts payable has changed by -$42.58 M (-43.40%)
What is Alnylam Pharmaceuticals quarterly accounts payable?
The current quarterly accounts payable of ALNY is $70.81 M
What is the all time high quarterly accounts payable for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high quarterly accounts payable is $98.09 M
What is Alnylam Pharmaceuticals quarterly accounts payable year-on-year change?
Over the past year, ALNY quarterly accounts payable has changed by -$3.04 M (-4.11%)